S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:KYMR

Kymera Therapeutics (KYMR) Stock Price, News & Analysis

$40.20
+0.03 (+0.07%)
(As of 03/28/2024 ET)
Today's Range
$39.35
$40.62
50-Day Range
$27.49
$43.57
52-Week Range
$9.60
$45.31
Volume
544,033 shs
Average Volume
801,419 shs
Market Capitalization
$2.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.89

Kymera Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
0.8% Downside
$39.89 Price Target
Short Interest
Bearish
13.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Kymera Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$20 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.16) to ($3.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.30 out of 5 stars

Medical Sector

911th out of 938 stocks

Biological Products, Except Diagnostic Industry

146th out of 148 stocks

KYMR stock logo

About Kymera Therapeutics Stock (NASDAQ:KYMR)

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

KYMR Stock Price History

KYMR Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Kymera Therapeutics Inc (KYMR)
KYMR May 2024 30.000 call
KYMR Aug 2024 20.000 put
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Piper Sandler Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views
Stifel Nicolaus Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)
Q4 2023 Kymera Therapeutics Inc Earnings Call
See More Headlines
Receive KYMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/29/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:KYMR
Fax
N/A
Employees
187
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.89
High Stock Price Target
$56.00
Low Stock Price Target
$24.00
Potential Upside/Downside
-0.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$-146,960,000.00
Net Margins
-187.00%
Pretax Margin
-186.99%

Debt

Sales & Book Value

Annual Sales
$78.59 million
Book Value
$7.12 per share

Miscellaneous

Free Float
50,925,000
Market Cap
$2.46 billion
Optionable
Optionable
Beta
2.30
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Bruce L. Booth DPHIL (Age 50)
    Ph.D., Co-Founder & Chairman
    Comp: $79.19k
  • Dr. Nello Mainolfi M.D. (Age 46)
    Ph.D., Co-Founder, President, CEO & Director
    Comp: $975.2k
  • Mr. Bruce N. Jacobs CFAMr. Bruce N. Jacobs CFA
    Chief Financial Officer
  • Dr. Jared A. Gollob M.D. (Age 59)
    Chief Medical Officer
    Comp: $637.81k
  • Dr. Jeremy G. Chadwick Ph.D. (Age 61)
    Chief Operating Officer
  • Ms. Ellen V. Chiniara Esq. (Age 65)
    J.D., Chief Legal Officer & Corporate Secretary
  • Ms. Karen Weisbach
    Head of People & Culture
  • Dr. Juliet Williams B.A Ph.D.
    Head of Research

KYMR Stock Analysis - Frequently Asked Questions

Should I buy or sell Kymera Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last twelve months. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KYMR shares.
View KYMR analyst ratings
or view top-rated stocks.

What is Kymera Therapeutics' stock price target for 2024?

12 Wall Street analysts have issued 12-month price targets for Kymera Therapeutics' stock. Their KYMR share price targets range from $24.00 to $56.00. On average, they anticipate the company's share price to reach $39.89 in the next twelve months. This suggests that the stock has a possible downside of 0.8%.
View analysts price targets for KYMR
or view top-rated stocks among Wall Street analysts.

How have KYMR shares performed in 2024?

Kymera Therapeutics' stock was trading at $25.46 on January 1st, 2024. Since then, KYMR stock has increased by 57.9% and is now trading at $40.20.
View the best growth stocks for 2024 here
.

When is Kymera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our KYMR earnings forecast
.

How were Kymera Therapeutics' earnings last quarter?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) announced its earnings results on Thursday, February, 22nd. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.19. The business earned $47.90 million during the quarter, compared to analysts' expectations of $41.94 million. Kymera Therapeutics had a negative trailing twelve-month return on equity of 34.83% and a negative net margin of 187.00%. The business's quarterly revenue was up 197.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.60) EPS.

What ETFs hold Kymera Therapeutics' stock?

ETFs with the largest weight of Kymera Therapeutics (NASDAQ:KYMR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Simplify Propel Opportunities ETF (SURI).

What other stocks do shareholders of Kymera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC), Checkmate Pharmaceuticals (CMPI), Burlington Stores (BURL), BigCommerce (BIGC) and KE (BEKE).

When did Kymera Therapeutics IPO?

Kymera Therapeutics (KYMR) raised $126 million in an initial public offering on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

Who are Kymera Therapeutics' major shareholders?

Kymera Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (9.62%), Price T Rowe Associates Inc. MD (9.62%), BVF Inc. IL (9.30%), Wellington Management Group LLP (8.12%), Vanguard Group Inc. (7.20%) and Vanguard Group Inc. (6.54%). Insiders that own company stock include Bruce Booth, Bruce N Jacobs, Bruce N Jacobs, Bvf Partners L P/Il, Ellen Chiniara, Jared Gollob, Jeffrey W Albers, Nello Mainolfi, Richard Chesworth and Venture Fund X LP Atlas.
View institutional ownership trends
.

How do I buy shares of Kymera Therapeutics?

Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KYMR) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners